C&EN White Paper
How affinity tags are speeding up malaria vaccine development
Brought to you by Thermo Fisher Scientific

The parasite that causes malaria has no clear biological target for researchers to target with a vaccine. Despite decades of development, only one malaria vaccine to date has been approved by the World Health Organization.

Researchers have a pipeline of malaria vaccine candidates in development and clinical trials. Antigens for each vaccine are manufactured using the same blueprint, which includes using a novel purification approach for a biotherapeutic: affinity chromatography.

Producing each antigen with the same affinity tag has enabled the team to streamline purification, keep costs down, and rapidly advance their vaccine candidates into the clinic.

Key Objectives:
  • How affinity tags can be used to manufacture biotherapeutics for challenging targets, such as malaria vaccines
  • A string of four amino acids, called a C-tag, can be attached to engineered biomolecules and used as a platform technology to accelerate vaccine development
  • The C-tag affinity system is a viable technology to produce vaccines compliant with good manufacturing practices

Brought to you by:
Thermo Fisher Scientific
Please complete the form to download the white paper.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy .

Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy